encorafenib


( Last Updated : September 16, 2021)
Generic Name:
encorafenib
Project Status:
Complete
Therapeutic Area:
Metastatic colorectal cancer
Manufacturer:
Pfizer Canada ULC
Brand Name:
Braftovi
Project Line:
Reimbursement Review
Project Number:
PC0233-000
Tumour Type:
Gastrointestinal
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
In combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Indications:
In combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open 17-Nov-20
Call for patient/clinician input closed 15-Jan-21
Clarification:

- Patient input submission received from Colorectal Cancer Canada and Colorectal Cancer Resource & Action Network

Submission received 16-Dec-20
Submission accepted 07-Jan-21
Review initiated 08-Jan-21
Draft CADTH review report(s) provided to sponsor for comment 24-Mar-21
Deadline for sponsors comments 05-Apr-21
CADTH responses on draft review report(s) provided to sponsor 03-May-21
Expert committee meeting (initial) 14-May-21
Draft recommendation issued to sponsor 31-May-21
Draft recommendation posted for stakeholder feedback 10-Jun-21
End of feedback period 24-Jun-21
Final recommendation issued to sponsor and drug plans 08-Jul-21
Final recommendation posted 26-Jul-21
Deadline for sponsor to submit redaction requests on draft CADTH review report(s) 22-Jul-21
CADTH review report(s) posted 16-Sep-21